Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Jan 03, 2024 5:19pm

115 Views

Post# 35809507

RE:RE:RE:RE:RE:RE:RE:“Second mouse gets the cheese “

Well I guess we shall know soon enough is cf is right or not as if we are under an nda as he suggested then the next news from onc has to be about the buyout.
I hope for once u r right cf as it would be a nice change and then everyone can finally put all this behind us.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 22, 2024